PolyPid PYPD
D-PLEX100 awaits November 28, 2026 FDA decision; Azurity targets early 2027 launch
- D-PLEX100 FiledSurgical Site Infection · controlled-release broad-spectrum antibiotic
$17.1B of 2025 infectious disease blockbuster sales lose US exclusivity by 2037, led by Biktarvy, Descovy. These 1 public biotech have 1 infectious disease treatment in Phase 3 or filed with the FDA, 1 of them already filed.
2025 sales each company reports from tracked infectious disease treatments losing US exclusivity by 2037. Big pharma has spent $9.2B on 1 infectious disease acquisitions since 2023. See the deals →
D-PLEX100 awaits November 28, 2026 FDA decision; Azurity targets early 2027 launch
Filed treatments are listed first. This shows where late-stage treatments are being developed, not which companies will be acquired.
Pipeline data and summaries from Readouts as of 13 November 2026; companies already acquired are left out.
Oncology · Immunology · Cardiometabolic · Neuroscience · Other areas